Journals / Viral Hepatitis Journal / 2020 / Cilt: 26 - Sayı: 1

Effect of Advanced Fibrosis Presence on Adherence to Hepatocellular Carcinoma Surveillance in Chronic Hepatitis C Patients with Sustained Virologic Response

Kalıcı Viral Yanıtı Elde Edilen Kronik Hepatit C Hastalarında İleri Fibrozis Varlığının Hepatoselüler Karsinom Tarama Uyumuna Etkisi

Pages
32–38
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

During the follow-up period, the median was 35 (13-124)months, 24 (6.1%) patients were diagnosed with HCC. 48.2%(n=40) of the patients observed screening guidelines, while 22.9%(n=19) did not follow the guidelines; 28.9% (n=24) did not havescreening.Conclusion: HCC screening in CHC patients with advanced fibrosisis not carried out in accordance with the guidelines.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Although hepatocellular carcinoma (HCC) screening isaccepted as standard care in patients with chronic hepatitis C (CHC)diagnosis, sustained viral response (SVR) has been obtained bytreatment and it is not certain what the condition is in the groupof patients with advanced fibrosis who are at increased risk fordeveloping HCC before treatment.
📊
Key Findings & Data:In this cohort of patients, thepractice of HCC was intended to be evaluated in real life conditions.Materials and Methods: Between 2007-2019, the informationcards of the patients diagnosed with CHC were retrospectivelyexamined.
💡
Conclusion & Impact:During the follow-up period, the median was 35 (13-124)months, 24 (6.1%) patients were diagnosed with HCC. 48.2%(n=40) of the patients observed screening guidelines, while 22.9%(n=19) did not follow the guidelines; 28.9% (n=24) did not havescreening.Conclusion: HCC screening in CHC patients with advanced fibrosisis not carried out in accordance with the guidelines.
🔬Design:Research Article
📍Scope:2007-2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Although hepatocellular carcinoma (HCC) screening isaccepted as standard care in patients with chronic hepatitis C (CHC)diagnosis, sustained viral response (SVR) has been obtained bytreatment and it is not certain what the condition is in the groupof patients with advanced fibrosis who are at increased risk fordeveloping HCC before treatment. In this cohort of patients, thepractice of HCC was intended to be evaluated in real life conditions.Materials and Methods: Between 2007-2019, the informationcards of the patients diagnosed with CHC were retrospectivelyexamined. Patients with advanced fibrosis,prior the treatment, whohad obtained SVR were enrolled in the study. HCC screening wasdefined as alpha-fetoprotein testing and liver imaging combined.HCC surveillance every 6 months or more was defined ascompliance with screening guidelines.Results: The number of patients in the study was 83 (n=32,cirrhosis). During the follow-up period, the median was 35 (13-124)months, 24 (6.1%) patients were diagnosed with HCC. 48.2%(n=40) of the patients observed screening guidelines, while 22.9%(n=19) did not follow the guidelines; 28.9% (n=24) did not havescreening.Conclusion: HCC screening in CHC patients with advanced fibrosisis not carried out in accordance with the guidelines.

Özet

Amaç: Kronik hepatit C (KHC) tanılı hastalarda, hepatoselüler karsinom (HCC) taraması standart bakım olarak kabul edilmesine rağmen, tedavi ile kalıcı viral yanıt (KVY) elde edilmiş olup, tedavi öncesi HCC gelişimi açısından artmış risk taşıyan ileri fibrozisli hasta grubunda durumun ne olduğu konusu kesinlik kazanmamıştır. Bu hasta kohortunda, HCC taraması pratiğinin, gerçek yaşam koşullarında değerlendirilmesi amaçlandı. Gereç ve Yöntemler: 2007-2019 tarihleri arasında, tanı almış KHC tanılı hastaların bilgi kartları retrospektif olarak incelendi. Tedavi öncesinde ileri fibrozisi olan ve KVY elde edilen hastalar çalışmaya alındı. HCC taraması tanımı, alfa-fetoprotein tetkiki ve karaciğer görüntülemesinin birlikte yapılması olarak yapıldı. HCC taramasının 6 ayda bir veya daha sık yapılması tarama kurallarına uyulması olarak tanımlandı. Bulgular: Çalışmaya dahil edilen hasta sayısı 83 idi (n=32, siroz). Ortanca 35 (13-124) ay olan takip süresi boyunca, 24 (%6,1) hasta HCC tanısı aldı. Hastaların %48,2’sinde (n=40) tarama kurallarına uyulduğu, %22,9’unda (n=19) kurallara uyulmadığı ve hastaların %28,9’unda (n=24) ise tarama yapılmadığı görüldü. Sonuç: İleri fibrozisi olan KHC hastalarında HCC taraması, kılavuz önerilerine uygun yapılmamaktadır.

🔖

Cite This Article

ŞİRİN, G., HÜLAGÜ, S. (2022). Effect of Advanced Fibrosis Presence on Adherence to Hepatocellular Carcinoma Surveillance in Chronic Hepatitis C Patients with Sustained Virologic Response. Viral Hepatitis Journal, Cilt: 26 - Sayı: 1, 32–38. https://ajindex.com/articles/646339

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Wang LS, D’Souza LS, Jacobson IM. Hepatitis C-A clinical review. J Med Virol. 2016;88:1844-1855
  2. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22:7824-7840
  3. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoglu S, Ergonul O. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21:1020-1026
  4. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-68
  5. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47-52
  6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108
  7. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557- 2576
  8. Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, Luketic VA, Sanyal AJ, Habib A, Mihas AA, Giles HC, Maluf DG, Cotterell AH, Posner MP, Fisher RA. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008;121:119-126
  9. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34(Suppl 1):69-78
  10. Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511
  11. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699
  12. Çelen MK, Akdemir İ, Bayan K. Cure in Chronic Hepatitis C! Does it Prevent the Risk of Hepatocellular Carcinoma? Flora 2018;23:84-87
  13. Nguyen TT, Gildengorin G, Truong A, McPhee SJ. Factors influencing physicians’ screening behavior for liver cancer among high-risk patients. J Gen Intern Med. 2007;22:523-526
  14. Wang C, Chen V, Vu V, Le A, Nguyen L, Zhao C, Wong CR, Nguyen N, Li J, Zhang J, Trinh H, Nguyen MH. Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B. Medicine 2016;95:e4744
  15. Palmer LB,